{"entity":{"id":"nct04557449","kind":"trial","name":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","aka":[],"tldr":"A phase 2 trial of Atirmociclib, Letrozole, Fulvestrant in prostate cancer, run by Pfizer, active and no longer recruiting.","summary":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors is a phase 2 interventional study registered as NCT04557449 by Pfizer, with 362 participants enrolled, started 2020-09-23 and due to reach its primary completion in 2026-09-23. Interventions recorded: PF-07220060, Letrozole, Fulvestrant, Midazolam, Enzalutamide. Conditions listed: Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04557449","url":"https://clinicaltrials.gov/study/NCT04557449"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["cdk46-inhibitor"],"targets":[],"drugs":["atirmociclib","letrozole","fulvestrant","enzalutamide"],"companies":["pfizer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04557449","phase":"2","setting":"A PHASE 1/2A STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS","sponsor":"Pfizer","participation":[{"nct":"NCT04557449","source":"https://clinicaltrials.gov/study/NCT04557449","fetchedAt":"2026-10-07T16:53:22.534Z","studySha256":"ec7e63c27a556f316de52608596f06bd62630334c27f5ce31635365b175861e8","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-08-20","leadSponsor":"Pfizer","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":362,"enrolmentType":"ACTUAL","siteCount":39,"recruitingSiteCount":0,"countries":["Argentina","China","Czechia","Japan","Mexico","Slovakia","United Kingdom","United States"]}],"started":"2020-09-23","startedType":"actual","enrolled":362,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04557449/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"cdk46-inhibitor","kind":"technology","name":"CDK4/6 inhibitors","route":"/technologies/cdk46-inhibitor/"}],"drug":[{"id":"atirmociclib","kind":"drug","name":"Atirmociclib","route":"/drugs/atirmociclib/"},{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/"},{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/"},{"id":"letrozole","kind":"drug","name":"Letrozole (and other aromatase inhibitors)","route":"/drugs/letrozole/"}],"company":[{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"}]}}